MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study
Publication
, Conference
Lawitz, E; Bashir, M; Shim-Lopez, J; Lee, J; Song, K; Chen, H; Harrison, S
Published in: JOURNAL OF HEPATOLOGY
2020
Duke Scholars
Published In
JOURNAL OF HEPATOLOGY
EISSN
1600-0641
ISSN
0168-8278
Publication Date
2020
Volume
73
Start / End Page
S132 / S132
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lawitz, E., Bashir, M., Shim-Lopez, J., Lee, J., Song, K., Chen, H., & Harrison, S. (2020). MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study. In JOURNAL OF HEPATOLOGY (Vol. 73, pp. S132–S132).
Lawitz, Eric, Mustafa Bashir, Jennifer Shim-Lopez, Jonathan Lee, Ken Song, Hubert Chen, and Stephen Harrison. “MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study.” In JOURNAL OF HEPATOLOGY, 73:S132–S132, 2020.
Lawitz E, Bashir M, Shim-Lopez J, Lee J, Song K, Chen H, et al. MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study. In: JOURNAL OF HEPATOLOGY. 2020. p. S132–S132.
Lawitz, Eric, et al. “MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study.” JOURNAL OF HEPATOLOGY, vol. 73, 2020, pp. S132–S132.
Lawitz E, Bashir M, Shim-Lopez J, Lee J, Song K, Chen H, Harrison S. MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study. JOURNAL OF HEPATOLOGY. 2020. p. S132–S132.
Published In
JOURNAL OF HEPATOLOGY
EISSN
1600-0641
ISSN
0168-8278
Publication Date
2020
Volume
73
Start / End Page
S132 / S132
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences